Dyne Therapeutics (NASDAQ:DYN) Lifted to “Hold” at StockNews.com

StockNews.com upgraded shares of Dyne Therapeutics (NASDAQ:DYN) from a sell rating to a hold rating in a research report report published on Saturday morning.

A number of other analysts also recently commented on the stock. Piper Sandler increased their price objective on shares of Dyne Therapeutics from $43.00 to $53.00 and gave the company an overweight rating in a report on Tuesday, August 13th. Morgan Stanley increased their price target on Dyne Therapeutics from $48.00 to $52.00 and gave the company an overweight rating in a report on Wednesday, August 14th. JPMorgan Chase & Co. boosted their price objective on Dyne Therapeutics from $39.00 to $43.00 and gave the stock an overweight rating in a research note on Tuesday, July 9th. Jefferies Financial Group raised their target price on Dyne Therapeutics from $36.00 to $42.00 and gave the stock a buy rating in a research note on Monday, May 20th. Finally, Guggenheim boosted their price target on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the company a buy rating in a research report on Thursday, August 15th. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of Buy and a consensus target price of $50.60.

Dyne Therapeutics Price Performance

Shares of NASDAQ:DYN opened at $46.82 on Friday. The business’s 50 day moving average price is $39.51 and its 200-day moving average price is $31.33. Dyne Therapeutics has a 1 year low of $6.40 and a 1 year high of $47.45. The firm has a market capitalization of $4.09 billion, a PE ratio of -11.79 and a beta of 1.07.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Monday, August 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.02. As a group, analysts expect that Dyne Therapeutics will post -3 earnings per share for the current year.

Insider Buying and Selling

In other news, SVP Richard William Scalzo sold 1,590 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $30.23, for a total value of $48,065.70. Following the sale, the senior vice president now directly owns 115,105 shares of the company’s stock, valued at approximately $3,479,624.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, COO Susanna Gatti High sold 80,000 shares of the stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $30.24, for a total transaction of $2,419,200.00. Following the transaction, the chief operating officer now owns 154,062 shares of the company’s stock, valued at approximately $4,658,834.88. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Richard William Scalzo sold 1,590 shares of Dyne Therapeutics stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $30.23, for a total value of $48,065.70. Following the completion of the transaction, the senior vice president now directly owns 115,105 shares of the company’s stock, valued at $3,479,624.15. The disclosure for this sale can be found here. In the last ninety days, insiders sold 163,676 shares of company stock valued at $5,270,510. 20.77% of the stock is currently owned by insiders.

Institutional Trading of Dyne Therapeutics

Several hedge funds have recently made changes to their positions in DYN. RA Capital Management L.P. purchased a new stake in Dyne Therapeutics during the 1st quarter worth approximately $140,666,000. Janus Henderson Group PLC grew its stake in shares of Dyne Therapeutics by 23,512.0% in the first quarter. Janus Henderson Group PLC now owns 2,675,240 shares of the company’s stock worth $75,915,000 after acquiring an additional 2,663,910 shares in the last quarter. Frazier Life Sciences Management L.P. purchased a new stake in shares of Dyne Therapeutics during the fourth quarter worth $15,758,000. Price T Rowe Associates Inc. MD raised its stake in shares of Dyne Therapeutics by 8,284.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,132,092 shares of the company’s stock valued at $32,141,000 after acquiring an additional 1,118,590 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Dyne Therapeutics by 47.7% in the first quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company’s stock valued at $97,669,000 after purchasing an additional 1,110,629 shares during the period. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.